XML 56 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity-Based Compensation - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Equity-based compensation expense $ 565,000 $ 1,625,000
Fulgent Therapeutics LLC | Discontinued Operations    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Equity-based compensation expense $ 0 $ 0
2015 Equity Incentive Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Vesting period 4 years  
Equity-based compensation options contractual term 10 years  
Equity-based compensation expense $ 0  
2016 Omnibus Incentive Plan | Employees Directors and Consultants | Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Shares available for issuance under the plan 2,038,480  
Restricted Stock Units (RSUs)    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected to be recognized, weighted-average period 3 years 7 months 6 days  
Unrecognized compensation expense $ 3,200,000  
Restricted Stock Units (RSUs) | 2015 Equity Incentive Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Vesting period 4 years  
Options    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Unrecognized compensation expense $ 1,200,000  
Expected to be recognized, weighted-average period 2 years 7 months 6 days